TY - JOUR
T1 - Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis
T2 - A 10-year longitudinal study from the EUSTAR database
AU - EUSTAR coauthors
AU - Wirz, Elina G.
AU - Jaeger, Veronika K.
AU - Allanore, Yannick
AU - Riemekasten, Gabriela
AU - Hachulla, Eric
AU - Distler, Oliver
AU - Airó, Paolo
AU - Carreira, Patricia E.
AU - Tikly, Mohammed
AU - Vettori, Serena
AU - Gurman, Alexandra Balbir
AU - Damjanov, Nemanja
AU - Müller-Ladner, Ulf
AU - Distler, Jörg
AU - Li, Mangtao
AU - Häusermann, Peter
AU - Walker, Ulrich A.
AU - Ananieva, Lidia
AU - Heitmann, Stefan
AU - Rednic, Simona
AU - Jimenez, Sergio
AU - Riccieri, Valeria
AU - Szmyrka-Kaczmarek, Magdalena
AU - Farge, Dominique
AU - Lapadula, Giovanni
AU - Matucci-Cerinic, Marco
AU - Guiducci, Serena
AU - Hunzelmann, Nicolas
AU - Rosa Pozzi, Maria
AU - Mihai, Carina
AU - Veale, Douglas
AU - Hesselstrand, Roger
AU - Mariok, Eduardo
AU - Smith, Vanessa
AU - Kucharz, Eugene J.
AU - Czirják, László
AU - Martinovic, Duska
AU - Solanki, Kamal
AU - Mihaela Ancuta, Codrina
AU - Sibilia, Jean
AU - Paola, Caramaschi
AU - Hassanien, Manal
AU - Kahl, Sarah
AU - Woods, Adrianne
AU - Vanthuyne, Marie
AU - Ruxandra, Ionescu
AU - Radominski, Sebastião C.
AU - Lo Monaco, Andrea
AU - Corrado, Ada
AU - Eyerich, Kilian
PY - 2016
Y1 - 2016
N2 - Objectives To longitudinally map the onset and identify risk factors for skin sclerosis and digital ulcers (DUs) in patients with systemic sclerosis (SSc) from an early time point after the onset of Raynaud's phenomenon (RP) in the European Scleroderma Trials and Research (EUSTAR) cohort. Methods 695 patients with SSc with a baseline visit within 1 year after RP onset were followed in the prospective multinational EUSTAR database. During the 10-year observation period, cumulative probabilities of cutaneous lesions were assessed with the Kaplan-Meier method. Cox proportional hazards regression analysis was used to evaluate risk factors. Results The median modified Rodnan skin score (mRSS) peaked 1 year after RP onset, and was 15 points. The 1-year probability to develop an mRSS ≥2 in at least one area of the arms and legs was 69% and 25%, respectively. Twenty-five per cent of patients developed diffuse cutaneous involvement in the first year after RP onset. This probability increased to 36% during the subsequent 2 years. Only 6% of patients developed diffuse cutaneous SSc thereafter. The probability to develop DUs increased to a maximum of 70% at the end of the 10-year observation. The main factors associated with diffuse cutaneous SSc were the presence of anti-RNA polymerase III autoantibodies, followed by antitopoisomerase autoantibodies and male sex. The main factor associated with incident DUs was the presence of antitopoisomerase autoantibodies. Conclusion Early after RP onset, cutaneous manifestations exhibit rapid kinetics in SSc. This should be accounted for in clinical trials aiming to prevent skin worsening.
AB - Objectives To longitudinally map the onset and identify risk factors for skin sclerosis and digital ulcers (DUs) in patients with systemic sclerosis (SSc) from an early time point after the onset of Raynaud's phenomenon (RP) in the European Scleroderma Trials and Research (EUSTAR) cohort. Methods 695 patients with SSc with a baseline visit within 1 year after RP onset were followed in the prospective multinational EUSTAR database. During the 10-year observation period, cumulative probabilities of cutaneous lesions were assessed with the Kaplan-Meier method. Cox proportional hazards regression analysis was used to evaluate risk factors. Results The median modified Rodnan skin score (mRSS) peaked 1 year after RP onset, and was 15 points. The 1-year probability to develop an mRSS ≥2 in at least one area of the arms and legs was 69% and 25%, respectively. Twenty-five per cent of patients developed diffuse cutaneous involvement in the first year after RP onset. This probability increased to 36% during the subsequent 2 years. Only 6% of patients developed diffuse cutaneous SSc thereafter. The probability to develop DUs increased to a maximum of 70% at the end of the 10-year observation. The main factors associated with diffuse cutaneous SSc were the presence of anti-RNA polymerase III autoantibodies, followed by antitopoisomerase autoantibodies and male sex. The main factor associated with incident DUs was the presence of antitopoisomerase autoantibodies. Conclusion Early after RP onset, cutaneous manifestations exhibit rapid kinetics in SSc. This should be accounted for in clinical trials aiming to prevent skin worsening.
UR - http://www.scopus.com/inward/record.url?scp=84940202098&partnerID=8YFLogxK
U2 - 10.1136/annrheumdis-2015-207271
DO - 10.1136/annrheumdis-2015-207271
M3 - Article
C2 - 26232495
AN - SCOPUS:84940202098
SN - 0003-4967
VL - 75
SP - 1285
EP - 1292
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
IS - 7
ER -